6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial

Authors :: Erik Mittra
Kjell Öberg
Andrew Eugene Hendifar
Beth Chasen
Martyn Caplin
T. Hobday
J. Strosberg
Matthew H. Kulke
Richard P. Baum
David L. Bushnell
Edward M. Wolin
M. Lopera Sierra
Dirk Jan Kwekkeboom
Philippe Ruszniewski
Source :: European Journal of Cancer. 51:S710
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.
Abstract: 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours : Results of the phase III NETTER-1 trial

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Internal medicine
medicine
Midgut
In patient
Progression-free survival
business

Full Text Access

Tools